Brammer Bio is a contract development and manufacturing organization (CDMO) serving companies seeking to develop and commercialize gene therapies.
Brammer is an experienced viral vector CDMO supporting gene therapies, and is focused on process and analytical development, and clinical and commercial supply. With more than a decade of experience, our over 500-strong, highly skilled team has managed over 100 client projects delivering first-in-human clinical materials to accelerate our client’s products from the laboratory to patients in need. We work in close collaboration with each client’s team to deliver successful programs. We are Manufacturing Personalized®. Through this, we enable the delivery of novel medicines to improve patient health with the potential to cure diseases. Brammer is Helping to Cure®.
Brammer’s 95,000 square-foot early clinical campus in Alachua, Florida consists of four buildings comprised of a process development and analytical development facility, adjacent to our CGMP phase I/II clinical manufacturing operation along with a QC laboratory, an office building and a warehouse building. Our CGMP facility accommodates spatially segregated viral vector processing in dedicated production suites to support early phase clinical trials.
Brammer's 66,000 square-foot phase III and commercial CGMP viral vector manufacturing facility is located in Cambridge, Massachusetts with an adjacent 49,000 square-foot warehouse and distribution center in Somerville, Massachusetts.
Our 50,000 square-foot Lexington, Massachusetts facility includes commercial ready Grade B clean rooms for viral vector manufacturing (operational in 2019).
In addition, we have business development and sales experts located in Fremont, California.
Brammer Bio was formed through a merger of Florida Biologix® and Brammer Biopharmaceuticals on March 31, 2016. At the time of the merger, Florida Biologix®, had a 10-year track record of providing development, early clinical phase manufacturing, and testing services, supporting biopharmaceutical clients with advanced therapeutic products and processes, including cell and gene therapies.
Florida Biologix® was established in 2006 as a component of the University of Florida with a mission to provide drug-development services to the biotechnology industry. It spun out of the university and went private in November 2015. Ampersand Capital Partners, the majority shareholder of Florida Biologix®, made an additional investment in the combined company and is the only institutional investor in Brammer Bio.
The Brammer Bio management team is led by Brammer founders Mark Bamforth, President and CEO; Dr. Richard Snyder, CSO; and by Chris Murphy, COO.